Nucana (NCNA) AI Stock Analysis

• Market Cap: $20.61M
• Dividend Yield: N/A
• Average Volume (3M): 209.21M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.89
• Revenue Growth: N/A
• EPS Growth: 35.70%
• Country: US
• Employees: 20
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.03
• Shares Outstanding: 381,295,870
• 10 Day Avg. Volume: 210,195,936
• 30 Day Avg. Volume: 209,206,862
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.14
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.02
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 28 Underperform
• Price Target: ―

Nucana's overall score is primarily impacted by its financial instability and negative valuation metrics. The significant lack of revenue generation and operational losses are major concerns. Despite showing strong cash management and low leverage, the company's technical indicators suggest a bearish trend, further weighing down the score. The poor valuation metrics, such as a negative P/E ratio, are offset by potential speculative interest due to the low stock price. The absence of notable earnings call insights or corporate events means these factors did not influence the score.

Nucana Business Overview & Revenue Model

Company Description

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

How the Company Makes Money

NuCana makes money primarily through the development and commercialization of its proprietary ProTide technology-based drugs. The company's revenue model is focused on advancing its pipeline of product candidates through clinical trials and eventually bringing them to market upon regulatory approval. Additionally, NuCana may generate income through strategic partnerships, licensing agreements, and collaborations with other pharmaceutical companies. These partnerships can provide upfront and milestone payments, as well as royalties on product sales. As a clinical-stage company, NuCana's earnings are currently dependent on its ability to successfully develop and commercialize its drug candidates.

Nucana Financial Statement Overview

Summary

Nucana's financials reflect the challenges faced by biotechnology firms in early development stages, with no revenue generation and consistent losses. While the company demonstrates strong cash management and low leverage, the shrinking equity and continued cash burn highlight financial vulnerabilities. The firm’s financial health would benefit significantly from achieving revenue growth and reducing operational losses.

Income Statement

Nucana's income statement shows no revenue generation over the analyzed period, which is typical for early-stage biotechnology companies. However, the continuous negative EBIT and net income indicate ongoing operational losses without revenue offset.

Balance Sheet

The company's high cash reserves relative to debt showcase prudent cash management, but the consistent decline in stockholders' equity raises concerns. The debt-to-equity ratio remains low, suggesting low financial leverage, yet the reduction in equity suggests potential risks if this trend continues.

Cash Flow

Nucana's cash flow statement reflects substantial negative operating cash flow, indicating cash burn typical of R&D-intensive biotech firms. The company maintains liquidity through financing, but the lack of free cash flow growth suggests an ongoing reliance on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-16.98M	-22.48M	-28.89M	-52.15M	-41.88M	0.00
Net Income	-14.63M	-19.00M	-27.63M	-32.02M	-40.53M	-30.68M
Balance Sheet
Total Assets	11.60M	14.77M	27.81M	58.25M	77.47M	107.79M
Cash, Cash Equivalents and Short-Term Investments	3.95M	6.75M	17.23M	41.91M	60.26M	87.36M
Total Debt	173.00K	190.00K	396.00K	639.00K	371.00K	645.00K
Total Liabilities	7.43M	8.82M	12.92M	19.75M	11.93M	8.56M
Stockholders Equity	4.17M	5.95M	14.89M	38.50M	65.55M	99.23M
Cash Flow
Free Cash Flow	-16.59M	-19.41M	-26.92M	-23.68M	-24.89M	-23.25M
Operating Cash Flow	-16.34M	-19.12M	-26.44M	-23.16M	-23.82M	-21.62M
Investing Cash Flow	25.00K	79.00K	2.89M	120.00K	-3.56M	-1.31M
Financing Cash Flow	7.24M	8.18M	-53.00K	-161.00K	-98.00K	61.80M

Nucana Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NCNA, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.07, and below the 200-day MA of 0.87, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 39.06 is Neutral, neither overbought nor oversold. The STOCH value of 27.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NCNA.

Nucana Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.61B	0.10	-63.03%	2.08%	16.34%	0.32%
SCNI	52 Neutral	$1.83M	0.36	138.38%	―	―	―
ELAB	37 Underperform	$3.18M	―	-130.35%	―	―	―
CNSP	32 Underperform	$4.55M	―	-477.53%	―	―	90.33%
NCNA	28 Underperform	$20.61M	―	-205.04%	―	―	35.70%
TNFA	―	$1.59M	―	-121.95%	―	―	―
VINC	15 Underperform	$1.44M	―	-431.29%	―	―	48.17%